IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
- Symbol
- IDXX
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $40.89B
- 52 week range
- 500.61 - 769.98
Valuation
- Share price
- $518.39 (close of 2026-10-02)
- P/E (TTM)
- 36.20x
- Price to book
- 25.36x
- Price to free cash flow
- 32.60x
- Enterprise value
- $41.79B
- Book value per share
- $20.44
Price performance
| Period | Change |
|---|---|
| 1 day | +0.12% |
| 5 days | -0.17% |
| 1 month | -3.82% |
| 3 months | -7.07% |
| 6 months | -8.98% |
| Year to date | -23.38% |
| 1 year | -18.21% |
| 3 years | +20.29% |
| 5 years | -16.92% |
| 10 years | +359.85% |
| All time | +54467.37% |
Members of Congress who disclosed IDXX trades
April McClain Delaney · Jefferson Shreve · Robert Bresnahan · Byron Donalds
Super investors holding IDXX
Terry Smith (Fundsmith LLP) · Polen Capital Mgmt (Polen Capital Management LLC) · Ken Griffin (Citadel) · Wallace Weitz (Weitz Investment Management) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc) · Bill Nygren (Harris Associates LP)
Profitability and growth
- Return on equity
- 65.99%
- Return on invested capital
- 45.61%
- Return on assets
- 31.62%
- Return on capital employed
- 61.76%
- Gross margin
- 61.80%
- Net margin
- 24.62%
- EBITDA margin
- 34.97%
- Revenue growth
- 10.42%
- Net income growth
- 19.33%
- Free cash flow growth
- 30.82%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.07%
- Current ratio
- 1.17x
- Net debt to EBITDA
- 0.56x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $4.30B
- Cost of revenue
- $1.64B
- Gross profit
- $2.66B
- EBITDA
- $1.51B
- Net income
- $1.06B
- Earnings per share
- $13.17
- Research and development
- $251.21M
- Shares outstanding
- 80.43M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $4.30B | $2.66B | $1.06B | $13.17 |
| 2024-12-31 | $3.90B | $2.38B | $887.87M | $10.77 |
| 2023-12-31 | $3.66B | $2.19B | $845.04M | $10.17 |
| 2022-12-31 | $3.37B | $2.00B | $679.09M | $8.12 |
| 2021-12-31 | $3.22B | $1.89B | $744.85M | $8.74 |
| 2020-12-31 | $2.71B | $1.57B | $581.78M | $6.82 |
| 2019-12-31 | $2.41B | $1.37B | $427.72M | $4.97 |
| 2018-12-31 | $2.21B | $1.24B | $377.03M | $4.34 |
| 2017-12-31 | $1.97B | $1.10B | $263.14M | $3.00 |
| 2016-12-31 | $1.78B | $975.44M | $222.04M | $2.47 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 61.80% | 24.62% | 65.99% | 45.61% |
| 2024-12-31 | 61.04% | 22.78% | 55.65% | 39.51% |
| 2023-12-31 | 59.82% | 23.08% | 56.92% | 41.99% |
| 2022-12-31 | 59.52% | 20.17% | 111.56% | 36.51% |
| 2021-12-31 | 58.76% | 23.17% | 107.95% | 51.51% |
| 2020-12-31 | 58.04% | 21.49% | 91.94% | 49.09% |
| 2019-12-31 | 56.73% | 17.77% | 240.53% | 52.74% |
| 2018-12-31 | 56.10% | 17.04% | -4083.52% | 87.60% |
| 2017-12-31 | 55.73% | 13.36% | -488.73% | 80.87% |
| 2016-12-31 | 54.94% | 12.51% | -205.19% | 75.76% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $180.07M | $374.84M |
| 2024-12-31 | $288.27M | $449.79M |
| 2023-12-31 | $453.93M | $622.88M |
| 2022-12-31 | $112.55M | $694.39M |
| 2021-12-31 | $144.45M | $775.21M |
| 2020-12-31 | $383.93M | $858.49M |
| 2019-12-31 | $90.33M | $698.91M |
| 2019-01-01 | $123.79M | $601.80M |
| 2018-12-31 | $123.79M | $601.80M |
| 2018-01-01 | $187.68M | $606.60M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $1.06B | $60.01M |
| 2024-12-31 | $808.08M | $60.30M |
| 2023-12-31 | $772.88M | $59.74M |
| 2022-12-31 | $394.15M | $49.77M |
| 2021-12-31 | $636.00M | $37.76M |
| 2020-12-31 | $541.11M | $30.95M |
| 2019-12-31 | $304.19M | $39.28M |
| 2018-12-31 | $284.33M | $25.16M |
| 2017-12-31 | $298.89M | $23.52M |
| 2016-12-31 | $274.16M | $19.89M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-02
- Consensus EPS estimate
- $3.70
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-04 | Jun/2026 | $3.95 |
| 2026-05-05 | Mar/2026 | $3.42 |
| 2026-02-02 | Dec/2025 | $2.93 |
| 2025-11-03 | Sep/2025 | $3.14 |
| 2025-08-04 | Jun/2025 | $3.31 |
| 2025-05-01 | Mar/2025 | $2.92 |
| 2025-02-03 | Dec/2024 | $2.40 |
| 2024-10-31 | Sep/2024 | $2.69 |
Filings and sources
- Company website
- idexx.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Illumina, Inc. (ILMN) · Waters Corp (WAT) · Mettler-Toledo International Inc (MTD) · IQVIA Holdings Inc. (IQV) · Quest Diagnostics Inc (DGX) · Agilent Technologies, Inc. (A) · Labcorp Holdings Inc. (LH) · Natera, Inc. (NTRA)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades